Trial tests smart treatment switch for tough blood cancer
NCT ID NCT07206264
Summary
This study is testing a new, personalized first treatment for older adults with mantle cell lymphoma, a type of blood cancer. It combines chemotherapy and targeted drugs, then adjusts the plan after four cycles based on how well the cancer is responding. The goal is to better control the disease and delay its return for as long as possible.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
-
Hebei Medical University Tumor Hospital
Shijiazhuang, Hebei, China
-
Shandong Cancer Hospital
Jinan, Shandong, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.